US6576646B1ExpiredUtility

Methods for treating cognitive impairments caused by traumatic brain injuries

95
Assignee: EISAI CO LTDPriority: Mar 3, 2000Filed: Jan 25, 2002Granted: Jun 10, 2003
Est. expiryMar 3, 2020(expired)· nominal 20-yr term from priority
Inventors:Raymond Pratt
A61K 31/445A61P 25/28A61P 25/00A61P 25/16
95
PatentIndex Score
59
Cited by
8
References
16
Claims

Abstract

The invention describes novel methods for treating and preventing cognitive impairments caused by traumatic brain injuries by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinestrease inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT(R).

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
       1. A method of treating one or more cognitive impairments caused by a closed head injury in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt thereof:                    
       or a stereoisomer thereof. 
     
     
       2. The method of  claim 1 , wherein the closed head injury is transient. 
     
     
       3. The method of  claim 1 , wherein the closed head injury is prolonged. 
     
     
       4. The method of  claim 1 , wherein the compound of formula (IV) is:                    
       or a stereoisomer thereof. 
     
     
       5. The method of  claim 1 , wherein the compound of formula (VI) is a compound of formula (VI) or a pharmaceutically acceptable salt thereof:                    
     
     
       6. The method of  claim 1 , wherein the compound of formula (IV) is a compound of formula (VII) or a pharmaceutically acceptable salt thereof:                    
     
     
       7. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is administered in an amount of about 1 mg to about 100 mg. 
     
     
       8. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is administered in an amount of about 5 mg to about 10 mg. 
     
     
       9. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is administered in an amount of about 5 milligrams. 
     
     
       10. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is administered in an amount of about 10 milligrams. 
     
     
       11. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is orally administered. 
     
     
       12. The method of  claim 11 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is orally administered in the form of a tablet. 
     
     
       13. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is topically administered to the epidermis. 
     
     
       14. The method of  claim 1 , wherein the patient is a human adult. 
     
     
       15. The method of  claim 1 , wherein the patient is a human child. 
     
     
       16. The method of  claim 1 , wherein the compound of formula (IV), the stereoisomer thereof, or the pharmaceutically acceptable salt thereof is administered by nasal inhalation.

Join the waitlist — get patent alerts

Track US6576646B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.